Sign In
Get Clay Free →

Suggestions

    Bennett Shum

    Improving public health by making medical-grade genomic tests accessible to all.

    Bennett Shum is the co-founder and CEO of Genepath, a medtech startup focused on next-generation newborn screening.12 He is also an Adjunct Senior Lecturer at the UNSW School of Biomedical Sciences and an industry mentor for the UNSW Founders startup program.13

    Background and Education::

    • Shum trained at the Garvan Institute and Harvard Medical School.2
    • He is an Adjunct Senior Lecturer at the University of New South Wales (UNSW).2

    Contributions and Achievements::

    • Shum helped implement genomic testing technology in hospitals across Australia.2
    • He is passionate about developing genomic solutions that can save lives globally.2
    • Genepath has pioneered research into next-generation newborn screening.1
    • He is a leader in peer-reviewed research regarding targeted gene sequencing tests for newborn screening.2
    • Shum's research interests include using genomic technologies for public health and understanding DNA variation through functional genomics.1

    Genepath's Work in Newborn Screening::

    • Genepath is working to expand population newborn screening programs through multidisciplinary research.1
    • The company's expertise lies in bioinformatics, software engineering, and molecular genetics, which facilitates the use of next-generation DNA sequencing for newborn screening.2
    • Genepath has designed next-generation sequencing platforms for newborn screening, including a targeted panel for treatable childhood genetic conditions and software designed for newborn screening.2
    • Targeted gene sequencing was technically validated in 2017 and clinically validated for spinal muscular atrophy in 2023 and cystic fibrosis in 2022.2
    • Feasibility and cost-effectiveness of high-throughput testing were achieved in 2023.2
    • Genepath is researching parent attitudes toward targeted gene sequencing for newborn screening to determine whether this technology should be incorporated into newborn screening programs.1
    • They are also investigating the cost-effectiveness of including familial hypercholesterolemia and biotinidase deficiency in newborn screening.1

    Highlights

    Jan 1 · genepath.au
    Our Team | Genepath Australia<br/><br/>
    Our Team | Genepath Australia<br/><br/>
    Oct 1 · genepath.au
    Genomic Newborn Screening Research | World leading - Genepath
    Jun 6 · genepathdx.com
    GenePath Diagnostics
    Aug 30 · nagra.com
    OPENTV APPOINTS BEN BENNETT CHIEF OPERATING OFFICER ...

    Related Questions

    What are Bennett Shum's main achievements at Genepath Laboratories?
    How did Bennett Shum and Glenn Bennett meet to co-found Genepath?
    What is the significance of Genepath's research in newborn screening?
    How does Bennett Shum's role as an Adjunct Senior Lecturer at UNSW influence his work at Genepath?
    What are the key challenges Bennett Shum has faced in implementing genomic technologies for public health?
    Bennett Shum
    Bennett Shum, photo 1
    Bennett Shum, photo 2
    Add to my network

    Location

    Greater Sydney Area